Clinical outcome of autologous hematopoietic stem cell infusion via hepatic artery or portal vein in patients with end-stage liver diseases.

Abstract

OBJECTIVE:

To investigate the efficacy of hematopoietic stem cell (HSC) transplantation via the hepatic artery vs. the portal vein for end-stage liver disease (ESLD).

METHODS:

Patients with hepatic decompensation were prospectively recruited from September 2010 to September 2012 to receive HSC transplantation via the hepatic artery or the portal vein. Liver function was examined at 3, 6, and 12 months after transplantation. Liver biopsy Results were analyzed using the Knodell score.

RESULTS:

Eighty patients (58 males and 22 females) were enrolled in the study. The Child-Pugh score was grade B in 69 cases, and grade C in the remaining 11 cases. HSC transplantation was performed via the portal vein in 36 patients and via the hepatic artery in 44 patients. ALT levels decreased while serum albumin levels increased significantly in both groups at 6 and 12 months after HSC transplantation (P<0.05 compared with pre-transplantation levels). Total bilirubin levels decreased significantly in both groups at 3, 6, and 12 months after HSC transplantation (P<0.05 compared with pre-transplantation levels). Additionally, prothrombin time decreased in both groups at 12 months after HSC transplantation (P<0.05 compared with pre-transplantation level). There were no significant differences in ALT, total bilirubin and prothrombin time between the two groups either before or after transplantation. Moreover, Knodell score decreased significantly at 6 and 12 months. Histological examination showed that liver cell edema, degeneration, necrosis, and inflammation were significantly relieved at 3, 6, and 12 months after transplantation. The incidence of portal vein thrombosis, upper gastrointestinal bleeding, and hepatic encephalopathy were 1.25%, 3.75%, and 2.5% respectively. The one-year survival rate was 100%.

CONCLUSIONS:

Autologous HSC transplantation improves liver function and histology in ESLD patients. The administration route of HSC has no significant impact on the efficacy of transplantation.

• Authors: Xiao-lun Huang, Le Luo, Lan-yun Luo, Hua Xue, Ling-ling Wei, Yu-tong Yao, Hai-bo Zou, Xiao-bing Huang, Yi-fan Zhu, Tian Zhang, Ping Xie, Mao-zhu Yang, Shao-ping Deng
• Journal: Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih (Chin Med Sci J) Vol. 29 Issue 1 Pg. 15-22 (Mar 2014) ISSN: 1001-9294 [Print] China
• PMID: 24698673 (Publication Type: Clinical Trial, Journal Article)

Topics

• Adult
• Aged
• Disease-Free Survival
• End Stage Liver Disease (pathology, therapy)
• Female
• Hematopoietic Stem Cell Transplantation (methods)
• Hepatic Artery
• Humans
• Infusions, Intra-Arterial
• Infusions, Intravenous
• Liver Function Tests
• Male
• Middle Aged
• Portal Vein
• Prospective Studies
• Treatment Outcome